A model framework for generating the evidence to demonstrate the efficacy of digital therapeutics so they can secure regulatory approval and reimbursement has been published by a trade orga
On Tuesday, Curebase announced a three-year clinical trial partnership with Meru Health, the study looking at the effectiveness of the latter’s 12-week treatment program, developed to reduc
Curebase has raised $40 million in second-round financing that will help it run more complex interventional trials for its biopharma clients, according to chief executive Tom Lemberg.
Prescription digital therapeutics (DTx) company Blue Note is starting a large-scale, decentralised trial of two cancer therapies that it hopes will lead to regulatory approval from the FDA.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.